Oncothyreon announces presentations at American Society Of Clinical Oncology (ASCO) Annual Meeting

SEATTLE, May 21 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that data highlighting the Company's two small molecule programs will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4 through 8, 2010 in Chicago.

Clinical data regarding Oncothyreon's product candidates PX-866 and PX-478 will be featured in the following poster presentations:

Final Results from a Phase I Dose-Escalation Study of PX-866, an Irreversible, Pan-Isoform Inhibitor of PI3 Kinase (http://abstract.asco.org/AbstView_74_42490.html)

    Date/Location: Monday, June 7, 2010, 8:00 a.m. to 12:00 p.m., S Hall A2
    Presenter: Antonio Jimeno, M.D., Ph.D., University of Colorado Cancer
               Center, Aurora, CO
    Abstract Number: 3089 (http://abstract.asco.org/AbstView_74_42490.html)

Results from a Phase I Dose-Escalation Study of PX-478, an Orally Available Inhibitor of HIF-1alpha (http://abstract.asco.org/AbstView_74_42538.html)

    Date/Location: Monday, June 7, 2010, 8:00 a.m. to 12:00 p.m., S Hall A2
    Presenter: Raoul Tibes, M.D, Ph.D., Virginia G. Piper Cancer Center and
               TGen, Scottsdale, AZ
    Abstract Number: 3076 (http://abstract.asco.org/AbstView_74_42538.html)

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.